Genprex Reports Q2 2026 Financial Results with $4.45 Million Net Loss

Genprex, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $4.45 million, a decrease of 5% from the $4.67 million loss recorded in the same period of 2025. For the first half of 2026, the company’s net loss was $8.91 million, slightly higher than the $8.64 million loss from the previous year. The company attributed the reduction in quarterly losses primarily to decreased professional services and equity-based compensation expenses. Research and development expenses increased by 7% to $2.68 million for the second quarter, driven by higher costs associated with preclinical and research activities related to its diabetes program and biomarker research.

Total operating expenses for the second quarter of 2026 were $4.48 million, down from $4.68 million in the prior year. General and administrative expenses decreased by 17% to $1.80 million, reflecting the company's ongoing efforts to implement cost-reduction strategies. The company reported other income of $37,290 for the quarter, significantly higher than the $6,881 recorded in the same quarter of 2025, primarily due to increased cash balances in interest-bearing accounts.

As of June 30, 2026, Genprex's total assets amounted to $17.14 million, a substantial increase from $10.16 million at the end of 2025. This growth was largely driven by a rise in cash and cash equivalents, which reached $15.15 million, compared to $7.83 million at the end of the previous year. The company’s stockholders' equity also saw a significant increase, rising to $14.80 million from $7.96 million, reflecting the issuance of common stock and the accumulation of additional paid-in capital.

In terms of strategic developments, Genprex has been actively advancing its clinical trials, particularly the Acclaim-1 and Acclaim-3 studies, which focus on its lead oncology product, REQORSA. The company is currently enrolling patients in the Phase 2a expansion portion of the Acclaim-1 trial, which combines REQORSA with AstraZeneca’s Tagrisso for treating late-stage non-small cell lung cancer. Additionally, Genprex has entered into a collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials, further enhancing its research capabilities.

Looking ahead, Genprex anticipates that its current cash reserves will fund operations and clinical trial activities into the second half of 2027. However, the company acknowledges the need for additional capital to support ongoing and future development efforts. Genprex plans to continue raising funds through equity offerings and other financing strategies, while also addressing material weaknesses in its internal controls over financial reporting. The company remains focused on advancing its gene therapy programs for oncology and diabetes, with the expectation of generating revenue from product sales once regulatory approvals are obtained.